BREAST NEOPLASMS

This study tests whether adding a targeted drug (Sac-TMT) to standard immunotherapy (pembrolizumab) and chemotherapy before surgery helps more people with high-risk, early-stage triple-negative or hormone-receptor-low/HER2-negative breast cancer achieve a complete response (no ca…

This study tests whether tirzepatide, a weight-loss drug, can help eliminate tiny amounts of cancer left after standard treatment in 48 patients with obesity or overweight and a high-risk type of early breast cancer. The goal is to see if weight loss leads to metabolic changes th…

This study offers ongoing access to the drug niraparib for people with ovarian or breast cancer who have already completed a previous niraparib trial and are still benefiting from the treatment. About 30 participants will continue taking niraparib to monitor long-term safety and …

This study tests two drugs, elacestrant and abemaciclib, in people whose breast cancer has spread to the brain. The goal is to see if the combination can shrink or control brain tumors. About 73 adults with ER-positive, HER2-negative breast cancer will take part. The study is cur…

This study tests a new drug called LY4337713, which delivers radiation directly to cancer cells that have a specific protein (FAP). It is for adults with advanced or spread-out cancers like pancreatic, breast, ovarian, colorectal, esophageal, stomach, or bile duct cancer. The mai…

This study tests whether adding the experimental drug BNT327 to standard chemotherapy helps people with a tough-to-treat type of breast cancer (triple-negative) that has spread and cannot be removed by surgery. About 558 participants will be randomly assigned to receive either BN…

This study watches how well Kisqali (ribociclib) combined with an aromatase inhibitor works in real-world settings for people with HR+/HER2- early breast cancer at high risk of coming back. About 3,250 participants will be followed to see how long they stay cancer-free, what side…

This study tests a new drug called LY4257496 that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced breast, prostate, colorectal, or endometrial cancer that has spread. The goal is to see if the drug is safe and can shrink …

This study tests a new drug, patritumab deruxtecan, against standard chemotherapy or another drug for people with a common type of advanced breast cancer (HR+/HER2-). The goal is to see if the new drug helps people live longer or keeps the cancer from growing. About 1000 particip…

This study is testing a new drug called patritumab deruxtecan in people with a type of advanced breast cancer (HER2-positive) that cannot be removed by surgery or has spread to other parts of the body. The main goals are to check the drug's safety and see if it can shrink or stop…

This study looks at whether a blood test (Signatera) can help decide when to start a targeted therapy (CDK4/6 inhibitor) in people with intermediate-risk HR+ HER2- breast cancer. About 725 participants will be monitored with regular blood draws; if the test detects cancer DNA, th…

This study compares two treatments for advanced estrogen receptor-positive (ER+) breast cancer that has stopped responding to standard therapies. About 297 participants will receive either a combination of elacestrant and capecitabine or capecitabine alone. The goal is to see if …

This study tests a new drug called izalontamab brengitecan (BMS-986507) against standard chemotherapy in about 500 people with advanced triple-negative or ER-low breast cancer who cannot receive immunotherapy. The drug is designed to target and kill cancer cells while sparing hea…

This study tests a combination of two drugs—disitamab vedotin and tucatinib—for people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combo is safe and can shrink or control tumors. About 172 adults with these cancers who have a…

This study tests a medicine called disitamab vedotin in people with advanced breast cancer that has spread and is hard to treat. Participants must have tumors with a protein called HER2 and have had prior treatment. Everyone receives the drug through a vein every two weeks to see…

This early-phase trial tests a new treatment for people with a type of stomach or esophagus cancer that has spread to the lining of the abdomen. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The cells are given …

This study tests a daily pill called (Z)-endoxifen, sometimes combined with a monthly shot (goserelin) that temporarily stops the ovaries from making estrogen. The goal is to see if this treatment can slow or stop the growth of estrogen-receptor-positive, HER2-negative breast can…

This study tests a new way of giving chemotherapy called adaptive therapy for people with advanced breast cancer that has gotten worse after standard treatments. The goal is to see if adjusting the chemo dose over time can keep the cancer under control longer and with fewer side …

This early-phase study tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors. It is a first-in-human trial, so the main focus is on …

This study tests whether adding a new drug (LY4064809) to standard hormone therapy and a CDK4/6 inhibitor can better control advanced HR+/HER2- breast cancer that has a PIK3CA mutation. About 920 adults who have not had prior treatment for advanced disease will participate. The g…

This study looks at whether a handheld robotic tool called HandX can help surgeons perform a nipple-sparing mastectomy through a single small side incision, reducing scarring and improving recovery. About 15 women who already need a mastectomy for early breast cancer or genetic r…

This study looks at whether adjusting the dose of chemotherapy drugs (5-FU or capecitabine) based on a person's DPYD gene test can reduce severe side effects. About 100 adults with certain cancers (like colorectal, breast, or head/neck) will take part. The goal is to see if perso…

This study tests a new drug (MK-2870) alone or with another drug (pembrolizumab) against standard treatments for people with a common type of advanced breast cancer (HR+/HER2-). About 1,200 participants whose cancer has spread or cannot be removed will be randomly assigned to one…

This study tests whether adding a new drug (patritumab deruxtecan) to standard chemotherapy and immunotherapy before surgery can eliminate more cancer cells in people with high-risk early-stage triple-negative or hormone-receptor-low breast cancer. About 372 participants will be …

This study is gathering images from 800 women who have suspicious breast findings (BI-RADS 4 or 5) to test a new 3D automated ultrasound system called ATUSA. The goal is to see if this radiation-free, operator-independent device can accurately detect breast cancer compared to sta…

This study tests whether a newer PET tracer, 68Ga-FAPI-46, can find more cancer spots than the standard tracer in people with ER-positive breast cancer. About 20 women with advanced or recurrent breast cancer will receive both types of scans. The goal is to see if the new tracer …

This study is testing two new imaging agents that light up breast cancer cells on PET scans. Researchers want to see if these agents can find tumors and their spread more accurately than current methods. About 200 women with breast cancer or suspected breast cancer will receive t…

This study looks at whether adding a special type of mammogram (contrast-enhanced mammography, or CEM) every two years to the standard yearly 3D mammogram can find breast cancer earlier in women who have already had breast cancer. About 1,500 women aged 30-79 who are at least one…

This study tests whether a new augmented reality (AR) imaging system can help surgeons remove all breast cancer during lumpectomy as well as the standard ultrasound method. About 94 women with breast cancer will be randomly assigned to get surgery guided by either the AR tool or …

This study is testing a new AI tool that collects family cancer history through WhatsApp to predict a woman's genetic risk for breast cancer. Researchers will compare the AI's predictions with standard genetic tests in 800 women already identified as high-risk by their doctors. T…

This study tests whether a dexamethasone mouthwash can reduce mouth sores caused by the cancer drug datopotamab deruxtecan (Dato-DXd). About 60 adults with advanced HER2-negative breast cancer or non-small cell lung cancer will use the mouthwash four times a day for the first fiv…

This study looks at whether a supervised exercise program with resistance training and relaxation can help breast cancer survivors build muscle and improve their quality of life. About 66 people who have finished treatment for early-stage breast cancer will take part. They will e…

This study tests whether a program of exercise and personalized nutrition, started right after a breast cancer diagnosis and continued through treatment, can improve fitness, strength, and quality of life. Researchers will enroll 66 women with early-stage breast cancer. The goal …

This study compares two approaches for breast cancer patients who need a mastectomy and radiation. The experimental group gets radiation before surgery with immediate reconstruction, while the standard group gets radiation after surgery with delayed reconstruction. Researchers wa…

This study tests a decision aid for women aged 70 and older with early-stage, low-risk breast cancer. The tool helps them and their doctors discuss treatment options, aiming to reduce aggressive treatments like mastectomy or radiation when not needed. About 402 participants will …

This study takes small samples of breast cancer that has spread to the brain or other organs and grows them in the lab as mini tumors (organoids). Researchers will test whether these organoids can predict how well a patient's cancer responds to chemotherapy or radiation. The goal…

This study aims to learn why breast cancer risks and outcomes vary among different people. Researchers will collect blood, tissue samples, and survey data from 800 adults in South Florida. The goal is to find genetic and non-genetic factors that may explain these differences.

This observational study tracks how the lymphatic system changes after radiotherapy in 40 women with breast cancer. Using a safe dye and special imaging, researchers look for early signs that might predict lymphedema (arm swelling). The goal is to find ways to prevent this side e…

This study aims to match breast cancer patients with the most effective experimental drugs based on their tumor's unique features. Up to 5,000 participants will receive standard chemotherapy plus an experimental agent before surgery. Researchers will use MRI scans, tissue, and bl…

This study looks at why some women with breast cancer have worse outcomes than others, especially African American and American Indian women. Researchers will collect medical and genetic information and also teach participants how to better communicate with their healthcare team.…

This study collects thousands of breast ultrasound images and has expert doctors label them. Then, different AI models are tested to see how accurately they can identify cancer compared to the experts. The goal is to build a standard way to evaluate AI for breast imaging, not to …

This study looks at genetic markers on breast cancer cells before and after chemotherapy. Researchers want to see how these markers change and which ones might predict if the cancer will come back. About 300 adults with stage II to IV breast cancer will take part. The goal is to …

This study aims to create a computer-based tool that can predict which cancer patients are at high risk of heart damage from certain treatments. Researchers will follow 600 patients in France for one year, collecting health data to train a machine learning model. The goal is to h…

This study is not testing a new treatment. Instead, it gathers information from about 1,800 people with advanced breast cancer that cannot be removed by surgery or has spread. The goal is to learn how many patients have each type of breast cancer and to understand their character…

This study is testing a mobile decision aid for breast cancer patients who have had surgery. Twenty participants will use the tool on their phones and share their thoughts out loud. Researchers will measure how much the tool improves knowledge about reconstruction options. The go…

This study looks at whether a protein called SGLT2 can help predict heart damage in people receiving chemotherapy for breast cancer. Researchers will measure SGLT2 levels in blood and cells before and after treatment. The goal is to find better ways to identify who is at risk and…

This study follows 3000 women with early-stage breast cancer to understand how treatments like surgery, chemo, and radiation affect their quality of life and cause side effects. Participants will fill out surveys and have heart, lung, and blood tests over time. The goal is to lea…

This study follows 30 women aged 18-70 who are having DIEP flap breast reconstruction after breast cancer surgery. Researchers will take blood samples before and after surgery to measure markers of inflammation and stress. The goal is to learn more about how the body heals and to…

This study follows 100 women who had breast cancer surgery and therapy to see how their muscle mass and body fat change over two years. Researchers will measure muscle strength and body composition regularly. The goal is to understand the long-term physical effects of cancer reco…

This study looks at why some breast cancer patients get diarrhea from the drug Abemaciclib while others don't. Researchers will compare the gut bacteria of 60 women who are already taking the drug. The goal is to find if certain bacteria protect against diarrhea, which could lead…

This study follows 800 adults with advanced HER2-positive, HER2-low, or HER2-ultralow breast cancer who are receiving the drug trastuzumab deruxtecan as part of their normal care in Germany. Researchers will track how long patients stay on treatment, their quality of life, and an…